D-captopril | 112243-90-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: D-captopril
• 英文别名: Captopril；(2R)-1-(3-Mercapto-2-methylpropanoyl)pyrrolidine-2-carboxylic acid；(2R)-1-(2-methyl-3-sulfanylpropanoyl)pyrrolidine-2-carboxylic acid
• CAS: 112243-90-0
• 化学式: C₉H₁₅NO₃S
• 分子量: 217.289
• InChiKey: FAKRSMQSSFJEIM-COBSHVIPSA-N

物化性质

• 沸点：
  427.0±40.0 °C(Predicted)
• 密度：
  1.272±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  D-captopril 、 巯基丁二酸单金(1+)盐 生成 1,4-dihydroxy-1,4-dioxobutane-2-thiolate;gold(1+);(2R)-1-(2-methyl-3-sulfanylpropanoyl)pyrrolidine-2-carboxylic acid
  参考文献：
  名称：

  ISAB A. A., J. INORG. BIOCHEM., 30,(1987) N 1, 69-75

  摘要：

  DOI：

文献信息

• THERAPEUTIC AGENT FOR DEPLETION OF AN UNWANTED PROTEIN POPULATION FROM PLASMA
  申请人：Pentraxin Therapeutics Limited

  公开号：EP1418905A1

  公开（公告）日：2004-05-19
• Therapeutic agent for depletion of an unwanted protein population from plasma
  申请人：Pentraxin Therapeutics Limited

  公开号：EP1820501B1

  公开（公告）日：2011-09-14
• MEDICINAL USE OF SERRULATANE DITERPENES
  申请人：The University Of Sydney

  公开号：EP3509574A1

  公开（公告）日：2019-07-17
• THERAPEUTIC AGENT
  申请人：Pepys Mark

  公开号：US20060014665A1

  公开（公告）日：2006-01-19

  The invention relates to an agent for the depletion of unwanted proteins from plasma comprising a plurality of ligands covalently co-linked to produce a complex with a plurality of proteins wherein at least two of the ligands are capable of being bound by ligand binding sites on the proteins and wherein the non-protein access agent excludes certain D-proline derivatives.
• Therapeutic agent
  申请人：Pepys Mark

  公开号：US20060122124A1

  公开（公告）日：2006-06-08

  Agent for the depletion of an unwanted protein population from the plasma of a subject, which agent comprises a plurality of ligands covalently co-linked so as to form a complex with a plurality of the proteins in the presence thereof, wherein at least two of the ligands are the same or different and are capable of being bound by ligand binding sites present on the proteins, wherein the agent is a non-proteinaceous agent other than a D-proline of the formula wherein R is the group R 1 is hydrogen or halogen; X is —(CH 2 ) n —; —CH(R 2 )(CH 2 ) n —; —CH 2 O(CH 2 ) n —; —CH 2 NH—; benzyl, —C(R 2 )═CH—; —CH 2 CH(OH)—; or thiazol-2,5-diyl; Y is —S—S—; —(CH 2 ) n —; —O—; —NH—; —N(R 2 ); —CH═CH—; —NHC(O)NH—; —N(R 2 )C(O)N(R 2 )—; —N[CH 2 C 6 H 3 (OCH 3 ) 2 ]—; —N(CH 2 C 6 H 5 )—; —N(CH 2 C 6 H 5 )C(O)N(CH 2 C 6 H 5 )—; —N(alkoxyalkyl)-; N(cycloalkyl-methyl)-; 2,6-pyridyl; 2,5-furanyl; 2,5-thienyl; 1,2-cyclohexyl; 1,3-cyclohexyl; 1,4-cyclohexyl; 1,2-naphthyl; 1,4-naphthyl; 1,5-naphthyl; 1,6-naphthyl; biphenylen; or 1,2-phenylen, 1,3-phenylen and 1,4-phenylen, wherein the phenylen groups are optionally substituted by 1-4 substituents, selected from halogen, lower alkyl, lower alkoxy, hydroxy, carboxy, —COO-lower alkyl, nitrilo, 5-tetrazol, (2-carboxylic acid pyrrolidin-1-yl)-2-oxo-ethoxy, N-hydroxycarbamimidoyl, 5-oxo[1,2,4]oxadiazolyl, 2-oxo-[1,2,3,5]oxathiadiazolyl, 5-thioxo[1,2,4]oxadiazolyl and 5-tert-butylsulfanyl-[1,2,4]oxadiazolyl; X′ is —(CH 2 ) n —; —(CH 2 ) n CH(R 2 )—; —(CH 2 ) n OCH 2 —; —NHCH 2 —; benzyl, —CH═C(R 2 )—; —CH(OH)CH 2 ; or thiazol-2,5-diyl; R 2 is lower alkyl, lower alkoxy or benzyl and n is 0-3, or a pharmaceutically acceptable salt or mono- or diester thereof.